

were analyzed was insufficient for any conclusive determination, it appears that more numerous substitutions in X, rt, surface, and core proteins may be introduced during persistent elevation of HBV DNA. However, the development of SHE in chronic hepatitis B may be related to an imbalance between viral replication and host immune response [Perrillo, 2001]. In the future, it may be necessary to measure polymorphisms in genes that determine the expression and function of the host immune response among patients with SHE.

In conclusion, we clarified the characteristics of patients who did not show elevations in HBV DNA after emergence of YMDD mutant. In patients with SHE, more substitutions were seen in the palm and fingers sub-domains than in those without SHE; these substitutions might act to restore viral replication of lamivudine-resistant mutants. In analysis of the full-length HBV genomic sequence, a greater number of substitutions in some proteins may be related to emergence of severe hepatitis due to lamivudine-resistant virus. Lamivudine-resistant HBV quasispices with multiple compensatory changes that can modulate viral replication should be considered of clinical relevance in patients undergoing prolonged therapy. New antiviral agents such as adefovir dipivoxil [Chin et al., 2001] and entecavir [Colonna et al., 2001] may be useful in patients with SHE in conjunction with careful virological monitoring.

REFERENCES

- Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY, Locarnini S. 2003. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure. *J Clin Virol* 27:111-116.
- Beasley RP, Hwang LW, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. *Lancet* ii:1229-1233.
- Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. 2002. Selection of hepatitis B virus polymerase mutations with enhanced replication by lamivudine treatment after liver transplantation. *Gastroenterology* 122:264-273.
- Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. *Hepatology* 27:1711-1716.
- Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE 4th, Isom H, Bowden S, Desmond P, Locarnini SA. 2003. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. *Hepatology* 37:27-35.
- Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, Isom H, Furman P, Locarnini S. 2001. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. *Antimicrob Agents Chemother* 45:2495-2501.
- Colonna RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B, Clark JM. 2001. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. *J Infect Dis* 184:1236-1245.
- Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). *J Virol* 75:4771-4779.
- Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. *N Engl J Med* 333:1657-1661.
- Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, Crowther L, Condry LD, Woessner M, Rubin M, Brown NA, the U.S. Lamivudine Investigator Group. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 341:1256-1263.
- Fu L, Cheng YC. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)-SddC(3TC) resistance. *Biochem Pharmacol* 55:1567-1572.
- Günther S, Li B-C, Miaka S, Krüger DH, Meisel H, Will H. 1995. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutations in immunosuppressed patients. *J Virology* 69:5437-5444.
- Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. 2000. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. *Hepatology* 32:847-851.
- Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S. 1999. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. *J Clin Microbiol* 37:310-314.
- Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. 2001. Fatal submassive hepatitis necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. *Clin Infect Dis* 33:403-405.
- Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF, the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of Lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med* 339:61-68.
- Leung N. 2000. Liver disease-significant improvement with lamivudine. *J Med Virol* 61:380-385.
- Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. *Hepatology* 30:567-572.
- Lin CL, Tsai SL, Lee TH, Chien RN, Liao SK, Liaw YF. 2005. High frequency of functional anti-YMDD and mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. *Gut* 54:152-161.
- Ling R, Harrison TJ. 1999. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. *J Gen Virol* 80:601-606.
- Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutations associated with 3TC and famciclovir administration are replication defective. *Hepatology* 27:628-633.
- Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C, Zoulim F. 2000. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. *Hepatology* 32:1078-1088.
- Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. *Hepatology* 29:939-945.
- Perrillo RP. 2001. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. *Gastroenterology* 120:1009-1022.
- Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. *Hepatology* 33:751-757.
- Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K. 1999. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. *J Hepatol* 30:743-748.
- Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2002. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. *J Hepatol* 37:824-830.
- Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J,

- Takagi K, Kumada H. 2003. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. *Intervirology* 46:182-189.
- Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. 2004. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. *J Virol* 78:8524-8535.
- Torresi J. 2002b. The virological and clinical significance of mutation in the overlapping envelope and polymerase genes of hepatitis B virus. *J Clin Virol* 25:97-106.
- Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, Locarnini SA, Manns M, Trautwein C, Bock TC. 2002a. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. *Virology* 299:88-99.
- Zollner B, Stoehr A, Plettenberg A, Feucht H, Schroter M, Schafer P, Laufs R. 2000. In vivo dynamics and pathogenicity of wild-type and resistant hepatitis B virus during long-term lamivudine monotherapy—Clinical note. *J Clin Virol* 17:183-188.



ELSEVIER

CLINICAL RESEARCH STUDY

Long-Term Outcome after Hepatitis B Surface Antigen Seroclearance in Patients with Chronic Hepatitis B

Yasuji Arase, MD,^a Kenji Ikeda, MD,^a Fumitaka Suzuki, MD,^a Yoshiyuki Suzuki, MD,^a Satoshi Saitoh, MD,^a Masahiro Kobayashi, MD,^a Norio Akuta, MD,^a Takashi Someya, MD,^a Tetsuya Hosaka, MD,^a Hitomi Sezaki, MD,^a Mariko Kobayashi,^b Hiromitsu Kumada, MD^b

^aDepartment of Gastroenterology and ^bHepatic Research Unit, Toranomon Hospital, Tokyo, Japan.

ABSTRACT:

PURPOSE: The aim of this study was to elucidate the long-term outcome after hepatitis B surface antigen (HBsAg) seroclearance in a large number of Japanese patients.

METHODS: We studied the biochemical, virologic, histologic, and prolonged prognoses of 231 Japanese patients with HBsAg seroclearance (median follow-up, 6.5 years). Serum alanine aminotransferase, serum hepatitis B virus (HBV) markers, liver histology, and clinical aspects were monitored. HBV-DNA levels were measured with the qualitative polymerase chain reaction assay. The mean age of patients with HBsAg seroclearance was 52 years.

RESULTS: After HBsAg seroclearance, 203 patients (87.9%) had normal alanine aminotransferase levels 1 year after HBsAg seroclearance. HBV-DNA showed positive results in 4 patients (1.7%) 1 year after HBsAg seroclearance. Thirteen patients were examined for histologic changes of the liver after HBsAg seroclearance. All patients showed marked improvement of necroinflammation of the liver, but only 2 of the 13 patients showed no liver fibrosis. Liver cirrhosis and hepatocellular carcinoma did not develop in any of the 164 patients without evidence of liver cirrhosis at the time of HBsAg seroclearance. Hepatocellular carcinoma developed in 2 of the 67 patients with liver cirrhosis at the time of HBsAg seroclearance. During the observation period, 15 patients died. However, the cause of death of these 15 patients was not related to liver disease, such as hepatocellular carcinoma, decompensated liver cirrhosis, and rupture of esophageal varices.

CONCLUSION: Our results suggest that HBsAg seroclearance confers favorable long-term outcomes in patients without hepatocellular carcinoma or decompensated liver cirrhosis at the time of HBsAg seroclearance © 2006 Elsevier Inc. All rights reserved.

KEYWORDS: Chronic hepatitis B; HBV-DNA; Seroclearance of hepatitis B surface antigen

Chronic hepatitis B virus (HBV) is a serious liver disease with significant mortality. In patients with chronic HBV infection, persistent viral replication is associated with ongoing necroinflammation in the liver and progressive liver damage.¹⁻³ Yang et al⁴ reported that the relative risk

of hepatocellular carcinoma was 9.6 among men who were positive for HBsAg alone and 60.2 among men who were positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), compared with men who were negative for both. Epidemiologic studies have shown that positivity for HBsAg is one of the most important risk factors for hepatocellular carcinoma. However, in patients with HBeAg seroclearance and marked reduction of serum HBV-DNA, the prognosis of the disease is generally improved.⁵⁻⁷ Therefore, marked reduction of HBV replication can possibly prevent hepatocellular carcinoma development. Moreover, HBsAg

The present work was supported in part by grants-in-aid from Okinaka Memorial Institute for Medical Research and Japanese Ministry of Health, Labor, and Welfare.

Requests for reprints should be addressed to Yasuji Arase, MD, Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan.

E-mail address: es9y-ars@asahi-net.or.jp

seroclearance has been associated with a good prognosis, including liver histology and liver function improvement and even prolonged survival.⁸⁻¹⁰

However, spontaneous remissions occur in a small proportion of patients during the natural history of chronic HBV infections. Seroclearance of HBsAg in patients with chronic HBV infection is unusual (0.4%-2% per year in white patients¹¹⁻¹³ and 0.1%-0.8% per year in Chinese patients⁹). Thus, until now, few studies have dealt with prognosis in Japanese patients with seroclearance of HBsAg.

A few previous studies have had conflicting results, with some suggesting that adverse complications are not rare in patients with HBsAg clearance,^{14,15} and others suggesting that spontaneous HBsAg seroclearance is excellent.¹⁶ These discrepancies might depend on concurrent hepatitis infection, age, and other factors. The present study excluded patients with concurrent hepatitis virus infection. Moreover, the main focus of this article is the survival time of patients with HBsAg seroclearance. Thus, we performed this study to elucidate the long-term outcome after HBsAg seroclearance in a large number of Japanese patients.

MATERIALS AND METHODS

Patients

From 1972 to 2002, a total of 5055 chronic HBsAg carriers, who were known to be seropositive for HBsAg for at least 6 months, were studied at Toranomon Hospital in Tokyo, Japan. After a mean follow-up period of 4 years (range 0.5-30 years), 231 patients were noted to have delayed HBsAg seroclearance, which is defined as persistent absence of HBsAg antigenemia by radioimmunoassay for at least 1 year and until the last examination. We excluded from the study all patients with: concurrent hepatitis C virus and hepatitis D virus; a history of alcohol abuse or autoimmune liver disease; clinical evidence of hepatocellular carcinoma at entry into the study on the basis of ultrasonography, alpha-fetoprotein levels (<200 ng/mL), and/or histology; or history or clinical evidence of complications of decompensated cirrhosis at enrollment (ie, ascites, encephalopathy, or icterus).

A total of 156 of 231 patients had spontaneous seroclearance of HBsAg; 46 patients had been given interferon monotherapy for 1 to 90 months; 14 patients had

been given steroid withdrawal monotherapy; and 12 patients had been treated with both steroids and interferon. The remaining 3 patients had been given 100 mg of lamivudine daily for more than 1 year. The total median dose of interferon monotherapy was 336 MU (range 168-

1890 MU). The patients treated with steroids were generally given prednisolone for 4 weeks, given in a single dose of 40 mg/day for 1 week, 30 mg/day for 1 week, 20 mg/day for 1 week, and then 10 mg/day for 1 week until it was abruptly withdrawn (total dose 700 mg). A total of 231 patients were followed up for more than 1 year after HBsAg seroclearance.

Methods

The time of entry into the study was defined as the time of serum HBsAg clearance as measured by radioimmunoassay. After HBsAg seroclearance, patients were followed up every 3 or 6 months or more frequently when their levels of alanine aminotransferase and α -fetoprotein were elevated. Follow-up studies

included clinical, biochemical, and virologic aspects, and hepatocellular carcinoma screening with ultrasonography and alpha-fetoprotein. Biochemical tests were measured using routine automated techniques and performed in the clinical pathology laboratories of Toranomon Hospital. HBsAg, anti-HBs, and antibody to hepatitis D virus were

CLINICAL SIGNIFICANCE

- HBsAg seroclearance confers favorable long-term outcomes in patients without hepatocellular carcinoma or decompensated liver cirrhosis at the time of HBsAg seroclearance.
- Patients with liver cirrhosis at the time of HBsAg seroclearance should be closely monitored for predictable complications such as hepatocellular carcinoma.
- Some patients had a trace of hepatitis B virus DNA at the fifth and/or tenth year after seroclearance of HBsAg and were followed on with the administration of steroids and/or immunosuppressive agents.

Table 1 Characteristics of subjects at the seroclearance of HBsAg

Characteristic	
N	231
Sex (male/female)	186/45
Age (years)	51 (23-66)
Body weight (kg)	67.5 (46.9-82.4)
HBV-genotype (A/B/C/D/F)	5/23/118/2/1
US (non-LC/LC)	164/67
Total protein (g/dl)	7.5 (6.5-9.3)
Albumin (g/dl)	4.2 (3.1-5.1)
Total bilirubin (g/dl)	0.7 (0.1-2.0)
AST (IU/L)	21 (10-219)
ALT (IU/L)	19 (6-946)
Hb (g/dl)	15.2 (12.0-17.4)
Platelet ($\times 10^4/\text{mm}^3$)	16.8 (8.4-32.5)
Follow-up period after disappearance of HBs antigen (year)	6.5 (1-23.6)

Data are number of patients or median (range). ALT = alanine aminotransferase; AST = aspartate aminotransferase; Hb = hemoglobin; US = ultrasonography




Figure 1 Cumulative appearance rate of the antibody to hepatitis B surface antigen (HBsAg) after seroclearance of HBsAg. IFN = interferon.

all assayed with commercially available radioimmunoassay kits. Antibody against HCV was detected with a third-generation enzyme-linked immunoassay (Ortho Diagnostic Japan, Tokyo, Japan). HBV genotype was determined with a previously reported method.¹⁷

Serum HBV-DNA level was measured with a commercially available quantitative polymerase chain reaction assay (Amplicor HBV, monitor, Roche Diagnostics, GmbH, Mannheim, Germany)¹⁸ 1 year after seroclearance of serum HBsAg. The sensitivity of HBV-DNA according to the manufacturer is approximately 400 copies/mL in quantitative polymerase chain reaction. Serum samples were conserved at -80° until use.

Status of liver cirrhosis was determined on the basis of liver biopsy and/or ultrasonographic findings. Ultrasonography was performed with a high-resolution, real-time scanner (model SSD-2000; Aloka Co., Ltd, Tokyo, Japan; Logic

700 MR; GE-Yokokawa Medical Systems, Tokyo, Japan). The diagnosis of liver cirrhosis was defined as having a score of more than 8 in an ultrasonographic scoring system based on liver surface, liver parenchyma, hepatic vessel, and spleen size, as reported by Lin et al.¹⁹

The diagnostic accuracy of ultrasonography for liver cirrhosis was at least 80%. This study was approved by the institutional review board of our hospital. The physicians in charge explained the purpose and method of this clinical trial to each patient, who gave their informed consent for participation.

Liver Histology and Ultrasonographic Findings

Liver biopsy specimens were obtained percutaneously or by peritoneoscopy using a modified Vim Silverman needle with an internal diameter of 2 mm (Tohoku University style, Kakinuma Factory, Tokyo, Japan), fixed in

Table 2 Predictive factors for appearance of anti-HBsAg

Factor	Category	Odds ratio	95% CI	P value
Interferon therapy	(-)/(+)	1/1.90	1.13-3.21	.016
Prednisolone withdrawal therapy	(-)/(+)	1/2.25	1.07-4.72	.032
Age (years)	<60/ \geq 60	1/0.500	0.248-1.01	.052
Total protein (g/dl)	<8/ \geq 8	1/1.84	0.90-3.76	.096
US	Non-LC/LC	1/0.71	0.430-1.16	.167
HBV-genotype	B/C	1/1.63	0.58-4.55	.350
Sex	Male/Female	1/1.34	0.72-2.50	.355
AST (IU/L)	\geq 38/<38	1/1.59	0.57-4.43	.375
Platelet ($\times 10^4/\text{mm}^3$)	\leq 20/ $>$ 20	1/1.20	0.700-2.06	.504
ALT (IU/L)	\geq 50/<50	1/1.28	0.46-3.55	.634

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; Hb = hemoglobin; HCV = hepatitis C virus; US = ultrasonographic findings; LC = liver cirrhosis; HBV = hepatitis B virus.

Table 3 Histological features of the 13 patients with HBsAg seroclearance

Patients	Age of HBsAg clearance, y	Histologic activity index before HBsAg seroclearance*				Histologic activity index after HBsAg clearance*			
		Periportal bridging necrosis	Intralobular degeneration and focal necrosis	Portal inflammation	Fibrosis	Periportal bridging necrosis	Intralobular degeneration and focal necrosis	Portal inflammation	Fibrosis
1	24	3	3	1	1	0	0	0	0
2	29	3	3	3	3	0	0	0	3
3	36	3	3	3	3	0	0	0	2
4	40	5	3	4	3	0	0	0	1
5	42	4	3	4	2	1	1	1	1
6	42	3	3	3	2	0	0	1	2
7	45	5	4	3	3	0	0	1	1
8	46	3	3	3	3	0	0	1	2
9	48	3	3	3	4	0	0	0	4
10	59	5	4	4	3	0	1	1	0
11	61	4	3	4	3	0	1	1	1
12	61	3	3	1	4	0	0	0	2
13	61	3	3	3	2	0	0	1	2

*Histologic activity index score: 0-10 for periportal bridging necrosis and 0-4 for intralobular degeneration and focal necrosis, portal inflammation, and fibrosis.
 †Interval-1: Interval between first biopsy before HBsAg clearance and last biopsy after HBsAg clearance. Interval-2: Interval between HBsAg clearance and last biopsy after HBsAg clearance.

10% formalin, and stained with hematoxylin-eosin, Masson's trichrome, silver impregnation, and periodic acid-Schiff after diastase digestion. The size of specimens for examination was more than 6 portal areas. Histopathologic interpretations of these 3- to 4- μ m-thick sections were made independently by experienced liver pathologists (YA and HK) who had no clinical information or knowledge of chronologic order of the biopsies in each pair. The biopsy specimens were scored according to the system of Knodell et al.²⁰

Patient Follow-Up

Clinical evaluation and biochemical and hematologic tests were performed at 2- to 6-month intervals. Thirty patients were lost to follow-up. Because the appearance of hepatocellular carcinoma was not identified in these 30 patients, they were considered as censored data in statistical analysis.²¹ Hepatocellular carcinoma was diagnosed by histology or the typical hypervascular characteristics observed on angiography, in addition to certain features of computed tomography and ultrasonography.

Statistical Analysis

Statistical analysis was performed with Fisher's exact test, Kaplan-Meier estimate, log-rank test, and a Cox proportional hazard model where appropriate. *P* values less than .05 were considered statistically significant. The SPSS software package (SPSS Inc., Chicago, Ill) was used to perform statistical analysis.

RESULTS

Changes of Liver Biochemistry After HBsAg Seroclearance

Table 1 shows the characteristics of the 231 patients who had seroclearance of HBsAg. These patients were classified into a liver cirrhosis group or a non-liver cirrhosis group by ultrasonographic findings. A total of 67 patients showed a finding of liver cirrhosis. Histologic evidence of liver cirrhosis before HBsAg seroclearance was seen in 47 patients.

The alanine aminotransferase test showed that 203 of 231 patients (87.9%) had normal alanine aminotransferase levels 1 year after seroclearance of HBsAg. Twenty-eight patients had elevated alanine aminotransferase levels (18 with fatty infiltration of liver, 3 with alcohol abuse, and 8 with unknown origin).

Changes of HBV Marker after HBsAg Seroclearance

The cumulative appearance of anti-HBs is shown in Figure 1. A Cox proportional hazards model was used to analyze the factors contributing to the appearance of anti-HBs (Table 2). The patients treated with interferon showed the high cumulative appearance of anti-HBs by




Figure 2 Hepatocellular carcinoma (HCC) appearance rate after seroclearance of HBsAg. LC = liver cirrhosis.

log-rank test. Anti-HBs became detectable in 50.2% of patients with spontaneous seroclearance of HBsAg and in 78.5% of patients treated with interferon at the fifth year after HBsAg seroclearance.

Next, we examined serum HBV-DNA level with the qualitative polymerase chain reaction assay (Amplicor HBV monitor). HBV-DNA showed positive results in 1.7% (3/231) 1 year after seroclearance of HBsAg.

Table 4 Recent studies on the outcomes following HBsAg clearance

Source	Status at clearance	No of cases	No of HBV alone	Follow-up, mo	Mean age, y	Outcomes	
						Decompensated LC	HCC
Fattovich et al ¹⁴	LC	32	30*	55	44	6	1§
Huo et al ¹⁵	Non-LC	55	32*	23	54	6	1§
Chen et al ¹⁶	Non-LC	189	146*	65.4	43	0	2§
	LC	29	17*	50.8	54	4†	1§
Yuen et al ¹⁰	LC or non-LC	92	92	51.1	42.6		5
Present	Non-LC	167	167	61.1	51	0	0
	LC	67	67	74.1	52.5	0	2

LC = liver cirrhosis; HCC = hepatocellular carcinoma.

*Remaining patients had concurrent virus of hepatitis C virus and/or HDV.

†Two of 4 patients had concurrent virus.

§These patients had concurrent virus.




Figure 3 Survival based on difference of age after HBsAg seroclearance.

Histologic Changes of Liver after HBsAg Seroclearance

Thirteen patients with normal alanine aminotransferase levels after HBsAg seroclearance were examined for histologic changes of the liver before and after HBsAg seroclearance (Table 3). The median age of HBsAg seroclearance for the 13 patients with assessable liver biopsy was 45 years (range 24-61 years). The median interval between liver biopsies before and after HBsAg seroclearance was 101.6 months (range 16.0-207.7 months). Moreover, the median interval between HBsAg seroclearance and liver biopsies after HBsAg seroclearance was 18.9 months (range 2.3-69.8 months). The histologic changes of liver biopsies before and after HBsAg seroclearance are listed in Table 3. All patients showed marked improvement of necroinflammation of the liver, but only 2 of the 13 patients showed no liver fibrosis.

Cirrhosis-related Complications and Hepatocellular Carcinoma Appearance Rates

Liver cirrhosis and hepatocellular carcinoma did not develop in any of the 164 patients without evidence of liver cirrhosis at the time of HBsAg seroclearance. Cumulative hepatocellular carcinoma appearance rates are shown in Figure 2 by the Kaplan-Meier method. Two patients with liver cirrhosis at the time of HBsAg seroclearance had an occurrence of hepatocellular carcinoma at 5 and 5.8 years after seroclearance of HBsAg. Cumulative hepatocellular carcinoma appearance rates were 2.5% in the 5th year and 5.5% in the 10th year in the liver cirrhosis group. Pathologic confirmation using fine-needle biopsy or surgically resected specimens showed hepatocellular carcinoma. On the other hand, none of the patients without liver cirrhosis had hepatocellular carcinoma. Table 4 shows recent studies on the outcomes after HBsAg sero-

Table 5 Predictive factors for death after HBsAg seroclearance

Factor	Category	Odds ratio	95% CI	P value
Age (years)	<60/≥60	1/3.42	1.24-9.45	.018
US	Non-LC/LC	1/2.12	0.80-6.12	.127
Sex	Female/Male	1/1.34	0.42-4.21	.620
Platelet ($\times 10^4/\text{mm}^3$)	>20/≤20	1/1.33	0.357-4.97	.670
AST (IU/L)	≥38/<38	1/0.437	0.19-12.40	.680
Total protein (g/dl)	<8/≥8	1/0.657	0.082-5.26	.693
ALT (IU/L)	≥50/<50	1/0.420	0.19-12.18	.693
HBV-genotype	B/C	1/1.03	0.20-5.27	.971

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; Hb = hemoglobin; HBV = hepatitis B virus; US = ultrasonography

clearance. These studies indicated that patients with hepatitis C virus have a high tendency for hepatocellular carcinoma.

Survival

Survivals are shown in Figure 3. During the observation period, 15 patients died of various causes; 8 died of malignant tumors (3 with gastric carcinomas, 2 with malignant lymphomas, 1 with tongue carcinoma, 1 with prostatic carcinoma, and 1 with ovarian carcinoma); 2 died of pneumonia; 3 died of heart failure; and 2 died of cerebral infarction. No patients died of liver failure or hepatocellular carcinoma. Hepatic decompensation did not develop in any patients after seroclearance of HBsAg. A Cox proportional hazards model was used to analyze the factors contributing to their survival: factors examined included age, gender, histologic findings, HBV genotype, and interferon administration. By Cox regression analysis, the relative risk of death incidence in patients aged less than 60 years was 3.58 compared with that of patients aged 60 years or more. Survival time was longer in patients aged less than 60 years ($P = .017$) (Table 5).

DISCUSSION

The results of this study indicate that patients with HBsAg clearance have a good prognosis. None of the patients with liver cirrhosis who had lost serum HBsAg progressed to decompensated liver cirrhosis. Moreover, no patients without liver cirrhosis with HBsAg clearance progressed to liver cirrhosis and/or hepatocellular carcinoma. Our findings agree with the published data by Chen et al¹⁶ (Table 4). However, 2 of 67 patients with liver cirrhosis at the time of HBsAg clearance had hepatocellular carcinoma during follow-up, as Huo et al¹⁵ showed. Fortunately, these 2 patients could be treated with radical resection.

Chen et al¹⁶ reported that the prognosis after spontaneous HBsAg seroclearance is excellent, except in patients with liver cirrhosis or concurrent hepatitis virus infection. On the other hand, Huo et al¹⁵ reported that adverse events were not rare in patients with chronic HBV infection even after HBsAg clearance. The discrepancy among these studies may be attributable to differences in the backgrounds of the patients who were followed up. These discrepancies might depend on concurrent hepatitis, severity of liver disease, ages, and other factors. For example, chronic hepatitis C virus infection is considered to be one of the major causes of hepatocellular carcinoma in many countries, and we suggest a role for hepatitis C virus in the origin of hepatocellular carcinoma in the patients with HBsAg clearance. Patients with hepatitis C virus-RNA after HBsAg seroclearance tend to have occurrences of hepatocellular carcinoma frequently when compared with patients without hepatitis C virus-RNA. Moreover, most asymptomatic carriers with seroclearance of HBsAg have a tendency not to consult a doctor. On the other hand, generally,

symptomatic carriers after seroclearance of HBsAg tend to consult a doctor and are followed up. Thus, hepatocellular carcinoma development rates might be high in clinical institutions with a high rate of symptomatic carriers.

In the present study, we assessed the prolonged prognosis in a large number of Japanese patients with HBsAg seroclearance. This article excludes the patients with concurrent hepatitis virus infection. Moreover, most asymptomatic carriers with HBsAg seroclearance and normalization of alanine aminotransferase could be followed up and were included for analysis. This was because most patients in our hospital were civil servants and were frequently examined with liver function tests.

Most patients had a good prognosis after HBsAg clearance, and thus good survival. Moreover, there was no significant difference in survival between the liver cirrhosis and non-liver cirrhosis groups. There was no significant difference in survival between those with HBV genotype B and those with HBV genotype C. Thus, most patients with HBsAg seroclearance also showed clinical improvement and prolonged survival. In fact, all 15 patients died of causes unrelated to liver cirrhosis and/or hepatocellular carcinoma. The Cox proportional hazard model indicated that only age was associated with survival.

Next, it is important to decide how long the patients with seroclearance of HBsAg should be followed up. Our present findings showed the following: (1) The patients with liver cirrhosis at the time of HBsAg seroclearance have a possibility of hepatocellular carcinoma appearance. (2) No patient without liver cirrhosis at seroclearance had hepatocellular carcinoma. Thus, considering cost-effectiveness, it seems reasonable to increase the interval of follow-up after HBsAg seroclearance for patients without liver cirrhosis with chronic HBV infection alone. However, patients with liver cirrhosis should be carefully followed up.

In regard to histologic changes after marked reduction of HBV, most patients showed improvement in liver histology.^{10,22-24} However, liver fibrosis resolves significantly less frequently and less quickly than necroinflammation. This may be because slight liver fibrosis can be reduced for a long period, but advanced liver fibrosis cannot be reduced sufficiently.

In regard to the appearance of anti-hepatitis Bs during follow-up, patients treated with interferon and/or CS showed the high cumulative appearance of anti-hepatitis Bs by log-rank test. This result is consistent with other studies that suggest immunomodulation of interferon^{25,26} and CS.^{27,28} The authors concluded that interferon and CS might stimulate the production of anti-HBs in vivo.

CONCLUSION

The prognosis after HBsAg clearance was excellent except in patients with liver cirrhosis. However, patients

with liver cirrhosis should be closely monitored for predictable complications.

ACKNOWLEDGMENT

The authors acknowledge the editorial assistance of Thomas Hughes.

References

- Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. *Hepatology*. 1988;8:493-496.
- De Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. *Ann Intern Med*. 1993;118:191-194.
- Viola LA, Barrison IG, Coleman JC, et al. Natural history of liver disease in chronic hepatitis B surface antigen carriers. *Lancet*. 1981;2:1156-1159.
- Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. *N Engl J Med*. 2002;347:168-174.
- Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. *Ann Intern Med*. 1993;119:312-323.
- Niederer C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. *N Engl J Med*. 1996;334:1422-1427.
- Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. *Hepatology*. 2002;35:1522-1527.
- Lindsay KL, Redeker AG, Ashcava M. Delayed HBsAg clearance in chronic hepatitis B viral infection. *Hepatology*. 1981;1:586-589.
- Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B infection: a prospective study. *Hepatology*. 1991;13:627-631.
- Yuen MF, Ho Wong DKH, Sahlon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. *Hepatology*. 2004;39:1694-1701.
- Sampliner RE, Hamilton FA, Iseri QA, et al. The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers. *Am J Med Sci*. 1979;277:17-22.
- Alward WJ, McMahon BJ, Hall DB, et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. *J Infect Dis*. 1985;151:604-609.
- Da Silva LC, Madruga CL, Carrilho FJ, et al. Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic B hepatitis: lack of correlation with hepatitis C and D virus infection. *J Gastroenterol*. 1996;31:696-701.
- Fattovich G, Glustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis. *Am J Gastroenterol*. 1998;93:896-900.
- Huo TI, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. *Hepatology*. 1998;28:231-236.
- Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B with or without concurrent infection. *Gastroenterology*. 2002;123:1084-1089.
- Usuda S, Okamoto H, Iwanari H, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. *J Virol Methods*. 1999;80:97-112.
- Kessler HH, Pierer K, Dragon E, et al. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. *Clin Diagn Virol*. 1998;9:37-43.
- Lin DY, Sheen IS, Chiu CT, et al. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. *J Clin Ultrasound*. 1993;21:303-308.
- Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology*. 1981;1:431-435.
- Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. *Biometrika*. 1983;62:205-209.
- Arase Y, Ikeda K, Murashima N, et al. Time course of histological changes in patients with a sustained biochemical and virological response to corticosteroid withdrawal therapy for chronic hepatitis B. *Am J Gastroenterol*. 1999;94:3304-3309.
- Perrillo RP, Brunet EM. Hepatic histologic and immunochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. *Ann Intern Med*. 1991;115:113-115.
- Chung HT, Lai CL, Lok AS. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. *Hepatology*. 1995;22:25-29.
- Koreman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. *Ann Intern Med*. 1991;114:629-634.
- Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. *N Engl J Med*. 1997;336:347-356.
- Nair PV, Tong MJ, Stevenson D, et al. A pilot study on the effects of prednisolone withdrawal on serum hepatitis B virus DNA and HBeAg in chronic active hepatitis B. *Hepatology*. 1986;6:1319-1324.
- Muller R, Vido I, Schmidt FW. Rapid withdrawal of immunosuppressive therapy in chronic active hepatitis B infection. *Lancet*. 1981;1:1323-1324.

Predictive Factors of Virological Non-Response to Interferon–Ribavirin Combination Therapy for Patients Infected With Hepatitis C Virus of Genotype 1b and High Viral Load

Norio Akuta,^{1*} Fumitaka Suzuki,¹ Hitomi Sezaki,¹ Yoshiyuki Suzuki,¹ Tetsuya Hosaka,¹ Takashi Someya,¹ Masahiro Kobayashi,¹ Satoshi Saitoh,¹ Sachiyo Watahiki,² Junko Sato,² Mariko Kobayashi,² Yasuji Arase,¹ Kenji Ikeda,¹ and Hiromitsu Kumada¹

¹Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan

²Liver Research Laboratory, Toranomon Hospital, Tokyo, Japan

Patients with high viral load ($\geq 1.0 \times 10^5$ IU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve high sustained virological response rates to interferon (IFN)/ribavirin combination therapy. Previous studies suggested that pretreatment amino acid (aa) substitution patterns in the HCV core region could affect virological non-response especially in patients who could not achieve HCV-RNA negativity during treatment. The present study evaluated 167 consecutive Japanese adults with high HCV genotype 1b viral load who received combination therapy for ≥ 24 weeks. A case-control study matched for age, sex, genotype, and viral load was conducted to investigate the predictive factors for virological non-response, especially absolute virological non-response (patients who could not achieve >2 log decline of HCV RNA from baseline during the initial 24 weeks of therapy). Virological non-response was identified in 26.3% of patients, and 45.5% of these were absolute virological non-responders. Multivariate analysis identified ribavirin dose < 11.0 mg/kg, moderate-to-severe hepatocyte steatosis, and substitutions of aa 70 and/or 91 in the core region as significant independent factors associated with virological non-response. The majority of absolute virological non-responders had such substitutions in the core region (95.0%), as well as substitution of glutamine at aa 70 and/or methionine at aa 91 (90.0%). In the present work, such substitutions significantly affected the viral kinetics in virological non-responders. The results suggest that viral, host, and treatment-related factors determine the response to IFN/ribavirin combination therapy in patients with high HCV genotype 1b viral load, and that amino acid substitution patterns in the core region is

potentially useful pretreatment predictor of virological non-response. *J. Med. Virol.* 78:83–90, 2006. © 2005 Wiley-Liss, Inc.

KEY WORDS: HCV; core region; hepatocyte steatosis; interferon; ribavirin; virological non-response; case-control study

INTRODUCTION

The aims of IFN therapy for chronic hepatitis C virus (HCV) infection include reduction of the risk of development of HCC and liver-related death by viral clearance, and then by normalization of alanine aminotransferase (ALT) even if viral clearance cannot be achieved [Ikeda et al., 1999; Akuta et al., 2005a]. The most effective initial therapy for viral clearance is the combination of interferon (IFN) and ribavirin administered for 48 weeks [Manns et al., 2001; Fried et al., 2002]. However, patients with high load of genotype 1b virus ($\geq 1.0 \times 10^5$ IU/ml), dominant in Japan, do not achieve high sustained virological response rates (less than 50%), even when the most effective combination treatment (pegylated IFN plus ribavirin) is administered for 48 weeks [Manns et al., 2001; Fried et al., 2002]. Furthermore, in genotype 1b, virological non-responders are seen frequently who do not achieve HCV-RNA

Grant sponsor: Ministry of Health, Labor and Welfare, Japan.

*Correspondence to: Norio Akuta, MD, Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-0001, Japan. E-mail: akuta-gi@umin.ac.jp

Accepted 3 October 2005

DOI 10.1002/jmv.20507

Published online in Wiley InterScience
(www.interscience.wiley.com)

negativity, as determined by polymerase chain reaction (PCR), during treatment. The underlying mechanism(s) of the different virological response to treatment in patients with 1b strain infection is still not clear.

Using multivariate analysis, Akuta et al. [2005b] identified hypoalbuminemia, pretreatment substitutions of amino acid (aa) 70 in the core region and pretreatment substitutions of aa 91 as independent and significant pretreatment factors associated with virological non-response, based on 48-week combination therapy of IFN plus ribavirin [Akuta et al., 2005b]. Especially, substitutions of arginine (R) by glutamine (Q) at aa 70, and/or leucine (L) by methionine (M) at aa 91 were significantly more common in virological non-responders. Decline of HCV-RNA levels during treatment in patients with specific substitutions in the core region was significantly less than in those without such substitutions [Akuta et al., 2005b].

The aims of the present study were the following: (1) to investigate the proportion of virological non-responders among a large number of Japanese adult patients who received combination therapy. Especially, to determine the proportion of absolute virological non-responders (i.e., ultimate resistant cases) who did not achieve a log decline of more than 2 from baseline HCV RNA during the initial 24 weeks of therapy, (2) to conduct a case-control study between groups matched for age, sex, genotype, and viral loads, to identify the predictive factors associated with virological non-response, including pretreatment amino acid substitution patterns in the core region, (3) to examine the initial viral kinetics in virological non-responders according to the virological features of the core region.

PATIENTS AND METHODS

Study Population

A total of 323 HCV-infected Japanese adult patients were recruited consecutively into the study of combination therapy with IFN (pegylated [PEG]-IFN α -2b or IFN α -2b) plus ribavirin for 24 weeks or more between 1999 and 2004 at Toranomon Hospital, Tokyo, Japan. Among these, 167 patients were selected in the present study based on the following criteria. (1) They were negative for hepatitis B surface antigen (radioimmunoassay, Dainabot, Tokyo, Japan), positive for anti-HCV (third-generation enzyme immunoassay, Chiron Corp., Emeryville, CA), and positive for HCV RNA qualitative analysis with PCR (Amplicor, Roche Diagnostic Systems, California). (2) They were naive to ribavirin therapy. (3) They were infected with HCV genotype 1b alone. (4) Each had a high viral load ($\geq 1.0 \times 10^5$ IU/ml) by quantitative analysis of HCV RNA with PCR (Cobas Amplicor HCV monitor v 2.0 using the 10-fold dilution method, Roche Diagnostics, Tokyo, Japan) at the start of treatment. (5) Each had chronic hepatitis, without cirrhosis or hepatocellular carcinoma (HCC), as confirmed by biopsy examination within the preceding 12 months of enrolment. (6) They had abnormal serum ALT levels (the upper limit of normal for ALT; 50 IU/L)

within the preceding 2 months of enrolment. (7) Their body weight was >40 kg. (8) All were free of coinfection with human immunodeficiency virus. (9) None had been treated with antiviral or immunosuppressive agents within the preceding 3 months of enrolment. (10) None was an alcoholic; lifetime cumulative alcohol intake was <500 kg (mild to moderate alcohol intake). (11) None had diabetes, other forms of hepatitis, such as hemochromatosis, Wilson disease, primary biliary cirrhosis, alcoholic liver disease, and autoimmune liver disease. (12) None of the females was pregnant or lactating mother. (13) All accepted treatment for 24 weeks or more as outlined in the study protocol, as well as repeated evaluation of HCV-RNA levels during treatment (at least once every month). (14) Each signed a consent form of the study protocol that had been approved by the Human Ethics Review Committee of Toranomon Hospital.

With regard to the treatment protocol, 21 (31.8%) patients received PEG-IFN α -2b at a dose of 1.5 μ g/kg subcutaneously each week plus oral ribavirin at 600–800 mg/day for 24 weeks or more. The remaining 45 (68.2%) patients received 6 million units of IFN α -2b intramuscularly each day for 24 weeks or more (daily for the initial 2 weeks, followed by three times per week for 22 weeks or more), and oral ribavirin at a dose of 600–800 mg/day for 24 weeks or more.

Table 1 summarizes the profiles and data of the 167 patients at the commencement of combination therapy of IFN plus ribavirin. They included 119 men and 48 women, aged 22–68 years (median, 54 years). The median total duration of treatment was 24 weeks (range, 24–48 weeks). In 46 (27.5%) patients, the dose of ribavirin was reduced during treatment due to a fall in hemoglobin concentration.

Patients who remained positive for HCV RNA based on quantitative and/or qualitative PCR analyses during and at the end of initial 24 weeks of combination therapy, were defined as virological non-responders. On the other hand, patients who became HCV RNA negative by qualitative PCR analysis during and/or at the end of initial 24 weeks were defined as virological responders. Virological non-responders who could not or could achieve a log decline of more than 2 from baseline of HCV RNA based on quantitative PCR analyses during the initial 24 weeks of combination therapy, were defined as absolute virological non-responders or relative virological non-responders, respectively.

Applying multivariate analysis, previous studies identified substitutions of aa 70 in the core region and substitutions of aa 91 as independent and significant pretreatment factors associated with virological non-response to combination therapy in patients with high viral load of genotype 1b [Akuta et al., 2005b]. Therefore, based on the larger numbers of patients, a case-control study was conducted to compare the substitution patterns in aa 70 and/or aa 91 of the core region, between virological non-responders and virological responders who were matched for age, sex, genotype, and viral load, in the present study.

TABLE I. Patient Profile and Laboratory Data at Commencement of Combination Therapy of Interferon Plus Ribavirin

n	167
Age (years)*	54 (22-68)
Sex (M/F)	119/48
Positive history of blood transfusion	50 (29.9%)
Positive family history of liver disease	52 (31.1%)
Genotype 1b	167 (100%)
High viral load ($\geq 1.0 \times 10^5$ IU/ml)	167 (100%)
Serum alanine aminotransferase (IU/l)*	90 (24-398)
Serum albumin (g/dl)*	3.8 (2.7-4.7)
Hemoglobin (g/dl)*	14.8 (11.1-18.2)
Platelet count ($\times 10^4$ /mm ³)*	17.3 (7.1-26.4)
Stage (F1/F2/F3) ^a	94/44/29

Data are number and percentages of patients, except those denoted by *, which represent the median (range) values.

^aStage of chronic hepatitis by Desmet et al. [1994]. ALT levels were abnormal in all patients at recruitment. Normal reference ranges: 6-50 IU/L for alanine aminotransferase and 3.9-5.2 g/dl for albumin.

Laboratory Tests

Blood samples were obtained at least once every month before, during, and after treatment, and were analyzed for ALT and HCV-RNA levels. The serum samples were frozen at -80°C within 4 hr of collection and were thawed at the time of measurement. HCV genotype was determined by PCR using a mixed primer set derived from the nucleotide sequences of NS5 region [Chayama et al., 1993]. HCV-RNA levels were measured quantitatively by PCR (Cobas Amplicor HCV monitor v 2.0 using the 10-fold dilution method, Roche Diagnostics, Tokyo, Japan) at least once every month before, during, and after therapy. The dynamic range of the assay was 5.0×10^3 to 5.0×10^6 IU/ml. Samples collected during and after therapy that showed undetectable levels of HCV-RNA ($< 5.0 \times 10^3$ IU/ml) were checked also by qualitative PCR (Amplicor, Roche Diagnostic Systems, California), which has a higher sensitivity than quantitative analysis, and the results were expressed as positive or negative. The lower limit of the assay was 50 IU/ml.

Histopathological Examination of Liver Biopsies

Liver biopsy specimens were obtained percutaneously or at peritoneoscopy using a modified Vim Silverman needle with an internal diameter of 2 mm (Tohoku University style, Kakinuma Factory, Tokyo, Japan), fixed in 10% formalin, and stained with hematoxylin and eosin, Masson's trichrome, silver impregnation, and periodic acid-Schiff after diastase digestion. All specimens for examinations contained six or more portal areas. Histopathological diagnosis was confirmed by an experienced liver pathologist (H.K.) who was blinded to the clinical data. Chronic hepatitis was diagnosed based on histological assessment according to the scoring system of Desmet et al. [1994]. Hepatocyte steatosis was graded as either none (absent), mild (less than 1/3 of hepatocytes involved), moderate (greater than 1/3 but less than 2/3 of hepatocytes involved), or severe (greater than 2/3 of hepatocytes involved) [D'Alessandro et al., 1991].

Nucleotide Sequencing of the Core and NS5A Gene

The core amino acids (aa) 1-191 and NS5A aa 2209-2248 (IFN-sensitivity determining region [ISDR]) [Enomoto et al., 1995, 1996] sequences were determined by the direct sequencing method using pretreatment sera of 66 patients. These sequences were compared with the consensus sequence of genotype 1b, which was determined by comparing the sequences obtained in this study and prototype sequence (HCV J) [Kato et al., 1990]. HCV RNA was extracted from serum samples at the start of treatment and reverse transcribed with random primers and MMLV reverse transcriptase (Takara Syuzo, Tokyo, Japan). DNA fragments were amplified by PCR using the following primers. (a) Nucleotide sequences of the core region: The first-round PCR was performed with CC11 (sense, 5'-GCC ATA GTG GTC TGC GGA AC-3') and e14 (antisense, 5'-GGA GCA GTC CTT CGT GAC ATG-3') primers, and the second-round PCR with CC9 (sense, 5'-GCT AGC CGA GTA GTG TT-3') and e14 (antisense) primers. (b) Nucleotide sequences of ISDR in NS5A: The first-round PCR was performed with ISDR1 (sense, 5'-ATG CCC ATG CCA GGT TCC AG-3') and ISDR2 (antisense, 5'-AGC TCC GCC AAG GCA GAA GA-3') primers, and the second-round PCR with ISDR3 (sense, 5'-ACC GGA TGT GGC AGT GCT CA-3') and ISDR4 (antisense, 5'-GTA ATC CGG GCG TGC CCA TA-3') primers. ([a], hemi-nested PCR; [b], nested PCR). All samples were denatured initially at 95°C for 15 min. The 35 cycles of amplification were set as follows: denaturation for 1 min at 94°C , annealing of primers for 2 min at 55°C , and extension for 3 min at 72°C with an additional 7 min for extension. Then 1 μl of the first PCR product was transferred to the second PCR reaction. The conditions for the second PCR were the same as the first PCR, except that the second PCR primers were used instead of the first PCR primers. The amplified PCR products were purified by the QIA quick PCR purification kit (Qiagen, Tokyo, Japan) after agarose gel electrophoresis and then used for direct sequencing. Dideoxynucleotide termination sequencing was performed with the Big Dye Deoxy

Terminator Cycle Sequencing kit (Perkin-Elmer, Tokyo, Japan).

To avoid false-positive results, the procedures recommended by Kwok and Higuchi [1989] to prevent contamination were strictly applied to these PCR assays. No false positive results were observed in this study.

Viral Kinetic Study of Virological Non-Response

Viral kinetics in the initial 24 weeks was evaluated in the two groups of absolute virological non-responders and relative virological non-responders at three time points (8, 12, and 24 weeks during treatment). Decline of HCV-RNA levels from baseline was expressed using \log_{10} of viral load at each time point, in comparison with the pretreatment viral load. For data analysis, \log_{10} of the cut-off value (5.0×10^3 IU/ml) was used for HCV-RNA values below the limit of detection.

Statistical Analysis

Non-parametric tests were used to compare the characteristics of the groups, including the Mann-Whitney *U* test, Chi-squared test, and Fisher's exact probability test. Multiple comparisons were examined by the Bonferroni test. Univariate and multivariate logistic regression analyses were used to determine the factors that significantly contributed to virological non-response. The odds ratios and 95% confidence intervals (95% CI) were also calculated. All *P* values less than 0.05 by the two-tailed test were considered significant. Variables that achieved statistical significance ($P < 0.05$) or marginal significance ($P < 0.10$) on univariate analysis were entered into multiple logistic regression analysis to identify significant independent factors. Potential predictive factors associated with virological non-response included the following variables: sex, age, history of blood transfusion, familial history of liver disease, body mass index, ALT, albumin, hemoglobin, platelet count, indocyanine green retention rate at 15 min (ICG R15), serum iron, serum ferritin, creatinine clearance, viremia level, pathological staging, hepatocyte steatosis, type of IFN, ribavirin dose relative to body weight, dose reduction, and pretreatment amino acid substitution in the core and ISDR of NS5A. Statistical analyses were performed using the SPSS software (SPSS, Inc., Chicago, IL).

RESULTS

The response to IFN/ribavirin combination treatment protocol among the 167 patients included virological non-response in 44 (26.3%) and virological response in 123 (73.7%). Furthermore, the first group of 44 virological non-responders consisted of 20 absolute virological non-responders (45.5%) and 24 relative virological non-responders (54.5%). To compare the pretreatment features between virological non-responders and virological responders, all 44 virological non-responders entered a case-control study along with 22 virological

responders. The latter group was selected from among the 123 because they matched patients of the virological non-response group with respect to sex, age, genotype, and viral load. Table II lists the clinical and virological features of patients who entered the matched case-control study.

Predictive Factors Associated With Virological Non-Response in Multivariate Analysis

The clinical and virological data listed in Table II for the whole population sample were analyzed to determine the factors that could predict virological non-response. Univariate analysis identified six parameters that tended to or significantly influenced the virological non-response. These included ribavirin dose according to body weight ($P = 0.019$), staging ($P = 0.024$), serum albumin ($P = 0.062$), hepatocyte steatosis ($P = 0.049$), and presence of aa substitution in HCV core in the pretreatment sample (substitution of aa 70, $P = 0.030$; and aa 70 and/or 91, $P = 0.006$). ISDR amino acid substitutions, which had been reported as one predictor of sustained virological response by IFN monotherapy [Enomoto et al., 1995, 1996], were not identified as a predictor of virological non-response to the combination therapy of IFN/ribavirin.

Multivariate analysis identified three parameters that independently influenced virological non-response; ribavirin dose ($P = 0.019$), hepatocyte steatosis ($P = 0.040$), and substitutions of aa 70 and/or 91 ($P = 0.005$) (Table III).

Treatment Efficacy According to Amino Acid Substitution Patterns in HCV Core Region

Frequencies of the substitution site at aa 70 were 60.0% (12/20), 37.5% (9/24), and 18.2% (4/22) in the three groups of absolute virological non-responders, relative virological non-responders, and virological responders, respectively. The proportion of such substitution site in absolute virological non-responders was significantly higher than that in virological responders ($P = 0.015$; Bonferroni test). Frequencies of substitution pattern of glutamine (Q) at aa 70 were 55.0% (11/20), 37.5% (9/24), and 13.6% (3/22) in the three groups of absolute virological non-responders, relative virological non-responders, and virological responders, respectively. The proportion of such substitution pattern in absolute virological non-responders was significantly higher than that in virological responders ($P = 0.014$; Bonferroni test).

The frequencies of substitution sites at aa 70 and/or 91, which were a significant predictor of virological non-response based on multivariate analysis, were 95.0% (19/20), 62.5% (15/24), and 40.9% (9/22) in the three groups of absolute virological non-responders, relative virological non-responders, and virological responders, respectively. The proportion of such substitution sites in absolute virological non-responders was significantly higher than that in relative virological non-responders ($P = 0.049$; Bonferroni test) and virological responders

TABLE II. Clinical and Virological Features of Patients Infected With HCV Genotype 1b With or Without Virological Response to Combination Therapy of Interferon Plus Ribavirin (Matched Case-Control study)

	Virological non-responders (case; n = 44)	Virological responders (control; n = 22)
Matching data		
Age (years)*	53 (24-67)	53 (20-64)
Sex (M/F)	33/11	17/5
Genotype 1b	44 (100%)	22 (100%)
High viral load ($\geq 1.0 \times 10^5$ IU/ml) ^b	44 (100%)	22 (100%)
Demographic data		
Positive history of blood transfusion	8 (18.2%)	6 (27.3%)
Positive family history of liver disease	11 (25.0%)	7 (31.8%)
Body mass index (kg/m ²) ^a	23.5 (17.3-32.3)	22.9 (19.3-28.8)
Laboratory data ^a		
Serum alanine aminotransferase (IU/L)	78.5 (24-247)	100.5 (43-276)
Serum albumin (g/dl)	3.7 (3.3-4.7)	3.9 (3.4-4.2)
Hemoglobin (g/dl)	14.7 (12.0-17.0)	15.0 (12.2-17.4)
Platelet count ($\times 10^4$ /mm ³)	16.2 (7.1-26.6)	15.7 (10.1-30.9)
ICG R15 (%) ^a	18 (7-49)	12 (7-26)
Serum iron (μ g/dl)	149 (51-253)	142 (52-308)
Serum ferritin (μ g/L)	158 (19-696)	136 (<10-644)
Creatinine clearance (ml/min)	95.7 (42.6-174.6)	106.3 (45.7-131.0)
Viral load (KIU/ml)	1,650 (160-5100)	1,700 (650-4900)
Histological findings		
Stage (F1/F2/F3) ^b	19/15/10	15/7/0
Hepatocyte steatosis (none-mild/ moderate-severe)	33/11	21/1
Treatment		
PEG-IFN α -2b/IFN α -2b	11/33	10/12
Ribavirin dose (mg/kg)*	10.8 (7.3-14.2)	11.4 (9.7-13.0)
Virological features		
Number of amino acid substitutions in ISDR (0/1-3/ ≥ 4 /ND)	26/11/3/4	10/10/2/0
Presence of amino acid substitutions sites in the core region		
aa 70	21 (47.7%)	4 (18.2%)
aa 91	22 (50.0%)	7 (31.8%)
aa 70 and/ or 91	34 (77.3%)	9 (40.9%)

Data are number and percentages of patients, except those denoted by *, which represent the median (range) values.

^aICG R15: indocyanine green retention rate at 15 min.

^bStage of chronic hepatitis by Desmet et al. [1994]. ALT levels were abnormal in all patients at recruitment. Normal reference ranges: 6-50 IU/L for alanine aminotransferase and 3.9-5.2 g/dl for albumin.

($P < 0.001$; Bonferroni test). Frequencies of substitution patterns of glutamine (Q) at aa 70 and/or methionine (M) at aa 91 were 90.0% (18/20), 62.5% (15/24), and 40.9% (9/22) in the three groups of absolute virological non-responders, relative virological non-responders, and virological responders, respectively. The proportion of such substitution patterns in absolute virological non-responders was significantly higher than in virological responders ($P = 0.002$; Bonferroni test). Figure 1 shows the association of aa substitution patterns at aa 70 and/

or 91 and response to combination therapy. There were no significant differences in other substitution sites, patterns and treatment efficacy among the three groups.

Viral Kinetics in Virological Non-Responderstpb

The decline of HCV-RNA levels at 8, 12, and 24 weeks relative to baseline was evaluated in absolute virological non-responders and relative virological non-responders. The decline at each time point was significantly lower in

TABLE III. Factors Associated With Virological Non-Response to Combination Therapy of Interferon Plus Ribavirin in 66 Patients Infected With HCV Genotype 1b, Identified by Multivariate Analysis

Factor	Category	Odds ratio (95% confidence interval)	P
Ribavirin dose (mg/kg)	1: <11.0	1	0.019
	2: ≥ 11.0	0.195 (0.050-0.765)	
Hepatocyte steatosis	1: None, mild	1	0.040
	2: Moderate, severe	14.299 (1.127-181.344)	
Substitution of aa 70 and/or 91	1: Absent	1	0.005
	2: Present	7.343 (1.841-29.285)	

Only variables that achieved statistical significance ($P < 0.05$) on multivariate logistic regression are shown.




Fig. 1. Frequencies of substitutions at amino acid sites 70 and/or 91 and substitution patterns (glutamine [Q] at aa 70 and/or methionine [M] at aa 91) in HCV core region, are evaluated in three groups of absolute virological non-responders, relative virological non-responders, and virological responders. The proportion of such substitution sites in absolute virological non-responders was significantly higher

than that in relative virological non-responders ($P = 0.049$; Bonferroni test) and virological responders ($P < 0.001$; Bonferroni test). The proportion of such substitution patterns in absolute virological non-responders was significantly higher than that in virological responders ($P = 0.002$; Bonferroni test).

absolute virological non-responders than in relative virological non-responders (8 weeks, $P = 0.001$; 12 weeks, $P < 0.001$; 24 weeks, $P < 0.001$). Figure 2 shows the decline of HCV-RNA levels in virological non-responders, according to aa substitutions of the core region. The decline at each time point was significantly lower in patients with substitution sites of aa 70 and/or 91 than in those without them (8 weeks, $P = 0.004$; 12 weeks, $P = 0.005$; 24 weeks, $P = 0.013$), and with substitution patterns of Q at aa 70 and/or M at aa 91 than in those without them (8 weeks, $P = 0.008$; 12 weeks, $P = 0.015$; 24 weeks, $P = 0.011$).




Fig. 2. Log changes in viral load from baseline at 8, 12, and 24 weeks during treatment, according to amino acid substitutions of the HCV core region. Bars within the boxes indicate the median value of log changes in viral load. The boxes denote the 25th to 75th centiles, the lower and upper bars the 10th and 90th centiles, respectively. The decline of HCV-RNA levels at each time point was significantly lower in patients with substitution sites of aa 70 and/or 91 than in those without them (Mann-Whitney U test).

J. Med. Virol. DOI 10.1002/jmv

DISCUSSION

Using multivariate analysis, Akuta et al. [2005b] identified pretreatment substitutions of aa 70 in the core region and substitutions of aa 91 as independent and significant pretreatment factors associated with virological non-response to 48-week combination therapy of IFN plus ribavirin. Substitutions of R by Q at aa 70 and/or L by M at aa 91, were significantly more common in virological non-responders. Furthermore, decline of HCV-RNA levels during treatment in patients with specific substitutions in the core region was significantly less than in those without such substitutions [Akuta et al., 2005b]. Using the same analysis, the present study based on a larger number of patients has also identified substitution patterns in aa 70 and/or aa 91 as independent and significant pretreatment factors associated with virological non-response to combination therapy, by a case-control study matched for age, sex, genotype, viral loads. Especially, most absolute virological non-responders, as ultimate resistant cases, were found to have such specific substitution sites (95.0%), and also had substitution patterns of glutamine (Q) at aa 70 and/or methionine (M) at aa 91 (90.0%).

Furthermore, such specific substitutions also significantly affected the viral kinetics in absolute virological non-responders and relative virological non-responders. Hence, we propose that the aa substitution pattern in the core region is useful as a pretreatment predictor of virological non-response to IFN/ribavirin combination therapy.

IFN- α and IFN- β bind to type I IFN receptor, and one major pathway in type I IFN signaling involve the Jak-STAT signaling cascade [Song and Shuai, 1998; Stoiber

et al., 1999; Auernhammer and Melmed, 2001; Alexander, 2002; Fujimoto and Naka, 2003; Lalvakolanu, 2003; Vlotides et al., 2004]. Previous studies reported that the HCV core region might be associated with resistance to the antiviral actions of IFN therapy involving the Jak-STAT signaling cascade [Blindenbacher et al., 2003; Bode et al., 2003; Melén et al., 2004; de Lucas et al., 2005]. The present study identified amino acid substitutions in the HCV core as a predictor of virological non-response to IFN/ribavirin combination therapy. This result suggests that substitutions of amino acids in the HCV core region might be associated with resistance to the antiviral actions of IFN therapy involving the Jak-STAT signaling cascade. Further studies that examine the structural and functional impact of core amino acid 70 and/or 91 substitutions during IFN/ribavirin combination therapy should be conducted in the future to confirm the above finding.

In the present study, virological non-response was noted in 26.3% of patients with high viral load of genotype 1b who received IFN/ribavirin combination therapy. This rate is worse than that of only 2.0% in patients with high viral load of genotype 2a treated with IFN alone [Akuta et al., 2002]. Akuta et al. [2002] examined patients infected with genotype 2a and reported that virological non-responders had higher viral load and one or more of other negative predictive factors associated with sustained virological response (i.e., lower total dose of IFN, moderate-to-severe grade of hepatocyte steatosis, lower levels of albumin, and ALT). Based on the above findings, it was concluded that a complex of negative predictive factors, including viral, host, and treatment-related factors, was the underlying cause of resistance to IFN treatment [Akuta et al., 2002]. Using multivariate analysis, the present study of patients with high viral load of genotype 1b who were treated with IFN/ribavirin, also identified lower ribavirin dose (as treatment-related factor), moderate-to-severe grade of hepatocyte steatosis (as host factor), and substitutions of aa 70 and/or 91 in the core region (as viral factor) as independent and significant factors associated with virological non-response. In this regard, another recent study did not identify ribavirin dose as an independent and significant predictor of virological non-response [Akuta et al., 2005b]. This discrepant finding may be due to the non-uniform dose of ribavirin used in the treatment of patients, which was not strictly adjusted according to body weight (e.g., 600 mg for weight ≤ 60 kg, and 800 mg for weight > 60 kg). Thus, the response to combination therapy of IFN/ribavirin is based on a dynamic tripartite interaction of the virus, host, and treatment-related factors. Further understanding of the complex interactions between these factors should facilitate the development of more effective therapeutic regimens.

Akuta et al. [2005b] reported that virological response to 48-week combination therapy of IFN/ribavirin was significantly influenced as negative predictive factor by the presence of pretreatment hypoalbuminemia, which might reflect liver function, based on multivariate

analysis. However, the same analysis in the present study did not identify serum albumin concentration as a significant predictor of virological non-response, although univariate analysis identified it as one of the parameters that tended to influence virological non-response. This discrepant finding could be due to one or more factors. The first is probably related to the design of the present study based on a case-control study matched for age and sex. The second is probably related to the relatively small number of patients in the previous study. A large-scale prospective study should be conducted in the future to establish the role of pretreatment hypoalbuminemia in virological non-response to 48-week IFN/ribavirin combination therapy.

In conclusion, the present study demonstrated that amino acid substitution patterns in the core region is a potentially useful predictor of virological non-response. One limitation of this study was that it did not examine other viral factors, such as amino acid substitutions in areas other than the core region and ISDR of HCV genome, as well as other host factors such as IFN-inducible protein kinase, MxA, and 2',5'-OAS protein [Gale et al., 1997; Wang and Floyd-Smith, 1997; Ronni et al., 1998; Antonelli et al., 1999; Akuta et al., 2003; Vlotides et al., 2004]. These factors should be investigated together with other factors in future studies. Moreover, further large-scale prospective studies are necessary to investigate whether the present results also explain resistance to combination therapy of IFN/ribavirin.

ACKNOWLEDGMENTS

This study was supported in part by a Grant-in-Aid from the Ministry of Health, Labor and Welfare, Japan.

REFERENCES

- Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2002. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: Therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. *J Hepatol* 37:831-836.
- Akuta N, Suzuki F, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2003. Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype 2a low viral load and response to interferon monotherapy. *J Med Virol* 69:376-383.
- Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. 2005a. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus. Multicourse interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. *Scand J Gastroenterol* 40:688-696.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2005b. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 48:372-380.
- Alexander WS. 2002. Suppressors of cytokine signaling (SOCS) in the immune system. *Nat Rev Immunol* 2:410-416.
- Antonelli G, Simeoni E, Turriziani O, Tesoro R, Redaelli A, Roffi L, Antonelli L, Pistello M, Dianzani F. 1999. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear

- cells with the response of patients with chronic hepatitis C to IFN- α therapy. *J Interferon Cytokine Res* 19:243–251.
- Auernhammer CJ, Melmed S. 2001. The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. *J Clin Invest* 108:1735–1740.
- Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, La Monica N, Heim MH. 2003. Expression of hepatitis C virus proteins inhibits interferon α signaling in the liver of transgenic mice. *Gastroenterology* 124:1465–1475.
- Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich PC, Häussinger D. 2003. IFN- α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. *FASEB J* 17:488–490.
- Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, Matsumoto T, Kobayashi M, Iwasaki S, Koyama S, Morinaga T, Kumada H. 1993. Genotypic subtyping of hepatitis C virus. *J Gastroenterol Hepatol* 8:150–156.
- D'Alessandro AM, Kalayouglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ, Pirsch JD, Hafez GR, Lorentzen D, Belzer FO. 1991. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. *Transplantation* 51:157–163.
- de Lucas S, Bartolome J, Carreno V. 2005. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. *J Infect Dis* 191:93–99.
- Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading and staging. *Hepatology* 19:1513–1520.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995. Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. *J Clin Invest* 96:224–230.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 334:77–81.
- Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncalves FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347:975–982.
- Fujimoto M, Naka T. 2003. Regulation of cytokine signaling by SOCS family molecules. *Trends Immunol* 24:659–666.
- Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. 1997. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. *Virology* 230:217–227.
- Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M. 1999. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. *Hepatology* 29:1124–1130.
- Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA* 87:9524–9528.
- Kwok S, Higuchi R. 1989. Avoiding false positives with PCR. *Nature* 339:237–238.
- Lalvakolanu DV. 2003. Alternate interferon signaling pathways. *Pharmacol Ther* 100:1–29.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. *Lancet* 358:958–965.
- Melén K, Fagerlund R, Nyqvist M, Keskinen P, Julkunen I. 2004. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. *J Med Virol* 73:536–547.
- Ronni T, Matikainen S, Lehtonen A, Palvimo J, Dellis J, Van Eylem F, Goetsch JF, Horisberger M, Content J, Julkunen I. 1998. The proximal interferon-stimulated response elements are essential for interferon responsiveness: A promoter analysis of the antiviral MxA gene. *J Interferon Cytokine Res* 18:773–781.
- Song MM, Shuai K. 1998. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. *J Biol Chem* 273:35056–35062.
- Stoiber D, Kovarik P, Cohnhey S, Johnston JA, Steinlein P, Decker T. 1999. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. *J Immunol* 163:2640–2647.
- Vlotides G, Sørensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, Zachoval R, Auernhammer CJ. 2004. SOCS-1 and SOCS-3 inhibit IFN- α -induced expression of the antiviral 2,5-OAS and MxA. *Biochem Biophys Res Commun* 320:1007–1014.
- Wang Q, Floyd-Smith G. 1997. The p69/71 2-5A synthetase promoter contains multiple regulatory elements required for interferon- α -induced expression. *DNA Cell Biol* 16:1385–1394.

Virological Outcomes in Patients Infected Chronically With Hepatitis B Virus Genotype A in Comparison With Genotypes B and C

Mariko Kobayashi,¹ Norio Akuta,² Fumitaka Suzuki,² Yoshiyuki Suzuki,² Yasuji Arase,² Kenji Ikeda,² Tetsuya Hosaka,² Satoshi Saitoh,¹ Masahiro Kobayashi,^{2*} Takashi Someya,² Junko Sato,¹ Sachiyo Watabiki,¹ Yuzo Miyakawa,³ and Hiromitsu Kumada²

¹Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan

²Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan

³Miyakawa Memorial Research Foundation, Tokyo, Japan

In a single hospital in Tokyo, the 87 patients infected persistently with hepatitis B virus (HBV) genotype A, the 413 with B, and the 3,389 with C were compared for virological outcome. Hepatitis B surface antigen (HBsAg) was cleared from the serum in 12% (3/26), 2% (2/112), and 3% (23/826) of patients with genotypes A, B, and C, respectively, at 5 years of follow-up ($P=0.0395$). Hepatitis B e antigen (HBeAg) was cleared from serum more frequently in patients with genotype B than those with A or C (78% [32/41] vs. 58% [11/19] or 45% [251/562], $P=0.00001$) at 5 years. Of the 45 individuals infected with genotype A and followed for 3 years or longer, HBeAg was more frequent (16% [3/19] vs. 73% [19/26], $P=0.0002$) and levels of HBV DNA higher (median <2.6 [range: <2.6 – 5.6] vs. >7.6 [<2.6 – >7.6] log copies/ml, $P=0.001$) in the 26 patients with biopsy-proven chronic hepatitis than the 19 asymptomatic carriers. Among the 26 hepatitis patients infected with HBV genotype A, decreases in HBV DNA were less frequent (20% [1/5] vs. 93% [13/14] or 86% [6/7], $P=0.0095$) and increases in serum levels of hyaluronic acid ≥ 10 ng/ml commoner (80% [4/5] vs. 14% [2/14] or 14% [1/7], $P=0.017$) in the patients who kept HBeAg than in those who seroconverted or who remained HBeAg-negative. In conclusion, patients persistently infected with HBV genotype A fare better than those with genotype B or C. However, high levels of HBV DNA continue in those in whom HBeAg persists along with fibrosis in the liver. *J. Med. Virol.* 78:60–67, 2006. © 2005 Wiley-Liss, Inc.

KEY WORDS: chronic hepatitis; cirrhosis; hepatitis B e antigen; hepatitis B surface antigen; hepatocellular carcinoma; sexual transmission

INTRODUCTION

There are an estimated 350 million people in the world who are persistently infected with hepatitis B virus (HBV), some of whom develop a spectrum of chronic liver disease ranging from chronic hepatitis through cirrhosis to hepatocellular carcinoma [Lee, 1997]. New HBV infections have been prevented by mass vaccination of neonates [Tsen et al., 1991; Chen et al., 1996] and immunoprophylaxis of babies born to mothers carrying HBV [Noto et al., 2003]. However, there are individuals who have been infected, and they need to be identified for receiving treatment as required. Clinical outcomes and the response to antiviral treatment are influenced by many host factors, such as ethnicity, gender, and the age at infection, as well as viral factors represented by HBV genotypes.

HBV has a partially double-stranded DNA genome of approximately 3,200 nucleotides (nt) [Tiollais et al., 1981]. Eight HBV genotypes have been classified by a sequence divergence in the entire genome exceeding 8% [Okamoto et al., 1988], and they are named by capital Alphabet letters from A to H [Okamoto et al., 1988; Norder et al., 1992; Stuyver et al., 2000; Arauz-Ruiz et al., 2002]. Recently, HBV genotypes have attracted an increasing attention because they influence the clinical outcome and treatment response in patients with chronic liver disease [Tsubota et al., 2001; Kao, 2002; Miyakawa and Mizokami, 2003; Schaefer, 2005; Yu et al., 2005]. Due to their uneven geographical

Grant sponsor: Ministry of Health, Labour and Welfare of Japan.

*Correspondence to: Masahiro Kobayashi, BS, Research Institute for Hepatology, Toranomon Hospital, 1-3-1, Kajigaya, Takatsu-ku, Kawasaki City 213-8587, Japan.
E-mail: vj7m-kbys@asahi-net.or.jp

Accepted 29 September 2005

DOI 10.1002/jmv.20504

Published online in Wiley InterScience
(www.interscience.wiley.com)

distribution, however, only two HBV genotypes prevail in most countries; the United States is the only exception with seven (A–G) genotypes [Chu et al., 2003; Westland et al., 2003]. Thus, genotypes A and D are common in Europe and India, while genotypes B and C are frequent in Asia [Magnius and Norder, 1995; Miyakawa and Mizokami, 2003]. Therefore, comparison has been restricted between patients infected with genotypes A and D, as well as those with B and C [Zhang et al., 1996; Mayerat et al., 1999; Kao et al., 2000; Orito et al., 2001; Chu et al., 2002; Thakur et al., 2002].

During 31 years from 1973 to 2003, 4,121 patients visited Toranomon Hospital in the Metropolitan Tokyo, and HBV genotypes were determined in them. There were 128 patients with genotype A, of whom 87 were chronically infected with HBV at the presentation. They were followed along with the 413 patients chronically infected with genotype B and the 3,389 with genotype C for seroclearance of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). Furthermore, patients with genotype A were grouped by the presence or absence of HBeAg at the presentation, as well as seroconversion during the follow-up, and they were compared for virological and clinical outcomes.

MATERIALS AND METHODS

Patients Chronically Infected With HBV

During 31 years from April 1973 to December 2003, genotypes of HBV DNA were determined in 4,121 patients with HBsAg in the Department of Gastroenterology at Toranomon Hospital in the Metropolitan Tokyo. Genotypes were A in 128 (3.11%) patients, B in 431 (10.46%), C in 3,434 (83.32%), D in 4 (0.97%), E in 1 (0.02%), and F in 3 (0.07%); they were not classifiable in the remaining 120 (2.91%) patients.

Of the 128 patients infected with HBV genotype A, 41 (32%) presented with acute hepatitis B as diagnosed by high-titered IgM antibody to hepatitis B core antigen. The remaining 87 (68%) patients were chronically infected with HBV genotype A when they visited our hospital. Their diagnoses were asymptomatic carriers with persistently normal ALT levels in 38 (44%) and chronic hepatitis in 39 (45%). In addition, nine (10%) patients presented with cirrhosis and one (1%) with hepatocellular carcinoma. Chronic hepatitis was diagnosed by liver biopsies performed under laparoscopy, and liver cirrhosis by liver biopsy and/or ultrasonographic images plus laparoscopic findings. Hepatocellular carcinoma was diagnosed by imaging modalities, such as ultrasonography, computed tomography, and magnetic resonance imaging, and by liver biopsy if necessary.

The 87 patients infected chronically with HBV genotype A had the median age of 34 years (range: 11–67 years), included 72 (83%) men and were followed for the median of 5.0 years (0.1–22 years). Only two (2%) had a history of blood transfusion, and three (3%) were co-infected with hepatitis C virus. They had the median

serum HBV DNA level at 4.2 log copies/ml, and HBeAg was detected in sera from 32 (37%). Subgenotypes of A [Bowyer et al., 1997; Sugauchi et al., 2004] were Aa (Asian or African type) in 5 (6%) and Ae (European type) in 65 (75%); they were not classifiable in the remaining 17 (19%).

Serological Markers of HBV Infection

HBsAg was determined by hemagglutination (MyCell; Institute of Immunology Co., Ltd., Tokyo, Japan) or enzyme-linked immunosorbent assay (ELISA) (ELISA, F-HBsAg; Sysmex, Kobe, Japan), and HBeAg by ELISA (ELISA, F-HBe; Sysmex). HBV DNA was determined by quantitative polymerase chain reaction (PCR) (Amplicor HBV Monitor Test; Roche Molecular Systems, Inc., New Jersey) and the results were expressed in log copies/ml within a detection range from 2.6 to 7.6.

Genotypes of HBV

The six major genotypes (A–F) were determined serologically by ELISA (HBV GENOTYPE EIA; Institute of Immunology). The method utilizes the combination of epitopes on preS2-region products that is specific for each genotype [Usuda et al., 1999, 2000]. Genotype G was determined by preS2 serotype for genotype D and HBsAg subtype adw, and H was recognized by serotype for genotype C and subtype adw, respectively; these combinations were specific for genotypes G and H, respectively [Kato et al., 2001, 2004].

Subgenotypes of A designated Ae prevalent in Europe and Aa frequent in Africa as well as Asia [Sugauchi et al., 2004] (corresponding to A' originally reported by Bowyer et al. [1997]), were determined by the nucleotide sequence in the S gene [Sugauchi et al., 2004]. Briefly, nucleic acids were extracted from serum and a sequence of the large S gene was amplified by PCR with nested primers. The first-round PCR was performed with BGF1 (sense, 5'-CTG TGG AAG GCT GGC ATT CT-3' [nt 2757–2776]) and BGR2 (antisense, 5'-GGC AGG ATA GCC GCA TTG TG-3' [nt 1050–1079]) primers, and the second-round PCR with PLF5Bm (sense, 5'-TGT GGA TCC TGC ACC GAA CAT GGA GAA-3' [nt 136–162]) and BR112 (antisense, 5'-TTC CGT CGA CAT ATC CCA TGA AGT TAA GGG A-3' [nt 865–895]) as well as BGF5 (sense, 5'-TGC GGG TCA CCA TAT TCT TG-3' [nt 2811–2830]) and BGR6 (antisense, 5'-AGA AGT CCA CCA CGA GTC TA-3' [nt 249–268]) for 35 cycles each (94°C, 1 min [5 min in the first cycle]; 53°C, 2 min; and 72°C, 3 min [7 min in the last cycle]). Amplification products were run on gel electrophoresis and stained with BIG Dye (Applied Biosystems, California), purified by Qquick PC purification kit (Qiagen, Hilden, Germany) and then sequenced in AGI Prism 310 Genetic Analyzer (Applied Biosystems). The large S-gene sequences were analyzed phylogenetically along with reference Aa and Ae sequences by six-parameter and neighbor-joining methods [Gojobori et al., 1982; Saitou and Nei, 1987].